Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients by Xueqin Chen et al.
Chen et al. Cancer Cell International  (2015) 15:43 
DOI 10.1186/s12935-015-0191-3PRIMARY RESEARCH Open AccessImpact of ABCG2 polymorphisms on the clinical
outcome of TKIs therapy in Chinese advanced
non-small-cell lung cancer patients
Xueqin Chen, Dadong Chen, Shaoyu Yang, Ruobing Ma, Yuelong Pan, Xin Li and Shenglin Ma*Abstract
Objective: The primary purpose of this study was to investigate the correlation between single nucleotide polymorphisms
(SNPs) of ATP binding cassette superfamily G member 2 (ABCG2) and outcome of tyrosine kinase inhibitions (TKIs)
therapy in Chinese advanced non-small-cell lung cancer (NSCLC) patients. The secondary objective was to identify
biomarkers to evaluate the response to treatment and outcome of the targeted therapy.
Methods: SNP genotyping (34 G/A, 421 C/A, 1143 C/T and −15622 C/T) of ABCG2 gene in 100 patients was performed
using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The clinical characteristics of 100
patients were collected. A total of 70 patients were treated with TKIs (gefitinib, erlotinib and icotinib). The association
between ABCG2 polymorphisms and clinical characteristics was evaluated. Kaplan-Meier survival curves were plotted for
overall survival (OS) and analyzed with the log-rank test.
Results: The three polymorphisms of the ABCG2 34 G/A, 421 C/A and 1143 C/T occurred more frequently compared
with −15622 C/T in Chinese advanced NSCLC patients. There was no association between ABCG2 polymorphisms and
clinical characteristics (p > 0.05). The median OS of patients with GG genotype at position 34 of the ABCG2 gene was
significantly shorter than those with GA or AA genotype (p < 0.05). No significant difference of OS was found in 421 C/A
and 1143 C/T polymorphisms (p > 0.05).
Conclusion: ABCG2 34 G/A may be a possible predictor of the clinical outcome of TKIs therapy in NSCLC patients.
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Tyrosine kinase inhibitions (TKIs) therapyBackground
Lung cancer is one of the most prevalent and fatal ma-
lignant neoplasm all over the world and non-small-cell
lung cancer (NSCLC) accounts for 80%–85% of all lung
cancer patients [1]. Approximately 80% of NSCLC pa-
tients are diagnosed as advanced (phase IIIA/B) or meta-
static (phase IV) stages of the disease [2], which results
in quite low 5-year survival rates, 8–14.1% for phase IIIA
and 1-5% for phase IIIB/IV [3]. Chemotherapy as the
standard treatment of advanced NSCLC has reached a
bottleneck with limited effects such as high relapse rates
and toxicity [4]. In recent years, targeted therapy has* Correspondence: mashenglin@medmail.com.cn
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unless otherwise stated.been widely applied in clinical practice to replace
chemotherapy. Tyrosine kinase inhibitors (TKIs), tar-
geted drugs of epidermal growth factor receptor (EGFR),
have been recently introduced for the treatment of
NSCLC [5]. Clinical trials indicated that gefitinib, erloti-
nib and icotinib, as EGFR-TKIs, are active and valid
treatment for patients with advanced or metastatic
NSCLC [6-8]. It has been reported that the patients with
advanced disease widely received targeted therapy [9].
Therefore, it is essential to find biomarkers to predict
the response to treatment and outcome of the targeted
therapy.
ATP binding cassette superfamily G member 2
(ABCG2) is a member of the ATP-binding cassette
(ABC) superfamily of multidrug transporters, which has
been involved in tumor cell resistance to anticancerhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the gastrointestinal tract and blood–brain barrier, where
it is thought to play a role in protection against xeno-
biotic exposure [11]. More than 80 single nucleotide
polymorphisms (SNPs) have been found in the ABCG2
gene [12]. The SNPs in ABCG2 are indicated to affect the
expression of ABCG2 protein. ABCG2 protein expression is
related to response of advanced NSCLC patients treated
with chemotherapy/targeted therapy [13-15]. ABCG2 421
C/A polymorphism is strongly associated with gefitinib-
induced diarrhea in Caucasian NSCLC patients [14].
Therefore, SNPs in the ABCG2 gene may influence the
pharmacological effects. Besides, SNPs in ABCG2 gene in
Asian population are different from other ethnicities [16],
However, the genetic polymorphisms of ABCG2 gene and
its impact on the outcome of targeted therapy in Chinese
advanced NSCLC patients are still not clearly demonstrated.
In this study, we tested the polymorphism of ABCG2
34 G/A (rs2231137), 421 C/A (rs2231142), 1143 C/T
(rs2622604) and −15622 C/T (rs7699188) in 100 Chinese
advanced NSCLC patients and analyzed the association
of SNPs in ABCG2 gene with clinical characteristics and
clinical outcome for NSCLC patients treated with TKIs
therapy. We expect the study can supply insights to val-
idate the role of ABCG2 polymorphisms for elective
treatment and to improve patients’ quality of life.
Materials and methods
Patients and treatment
A total of 100 patients with ECOG performance status of
0 to 2, and pathology and cytology confirmed advanced or
metastatic NSCLC were enrolled into this study between
April 2012 and January 2014 in Hangzhou, China. TKIs
targeted therapy was implemented in 70 NSCLC patients
and the other therapy was implemented in the remaining
patients. In this study, clinical outcome was only mea-
sured in the TKIs targeted therapy, not others. Patients
subjected to TKIs targeted therapy were treated with gefi-
tinib (Astrazeneca pharmaceutical co., LTD, Wuxi, China)
at a dose of 250 mg once a day or erlotinib (Roche
pharmaceuticals co., LTD, Shanghai, China) at a dose of
150 mg once daily or icotinib (Zhejiang beida pharma-
ceutical co., LTD, Hangzhou, China) at a dose of 125 mg
three times a day until disease progression or intolerable
toxicity. All patients received chest CT every 2 months
after 1 month of therapy.
The efficacy of TKIs therapy was clarified as complete
response (CR), partial response (PR), stable disease (SD)
and progression disease (PD) according to the Response
Evaluation Criteria In Solid Tumors (RECIST) 1.1 [17].
Patients of CR, PR and SD for more than 6 months were
considered as sensitive to treatment. Patients of SD for
less than 6 months and PD were considered as resistant
to treatment. Progression-free survival (PFS) was definedas the duration in month from start of TKI therapy to
disease progression. Overall survival (OS) was calculated
from the time of diagnosis until death from any cause.
All patients agreed to participate in this study and signed
written informed consent. This study was approved by the
Institutional Review Board of Nanjing Medical University
Affiliated Hangzhou Hospital and performed in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines.
DNA extraction
Blood samples were collected before TKIs therapy and
kept in a microcentrifuge tube containing ethylenedi-
amine tetra-acetic acid (EDTA). Genomic DNA was ex-
tracted from whole blood using a DNA purification kit
(Flexi Gene DNA Kit, Qiagen, Hilden, Germany). The
concentration of genomic DNA was determined with
NanoDrop 1000 (Thermo Scientific, Wilmington, USA)
and then diluted to a standard of 25 ng/μl.
Analysis of ABCG2 polymorphisms
The ABCG2 34 G/A was amplified using the primers
ABCG2 34 G/A Forward (5′-ACGTTGGATGTCAGGTC
ATTGGAAGCTGTC-3′), Reverse (3′-ACGTTGGATGGA
TGTCTTCCAGTAATGTCG-5′), and UEP_SEQ which
means the primer for single base extension reaction
(GTGTCGAAGTTTTTATCCCA). The ABCG2 421 C/A
was amplified using the primers ABCG2 421C/A Forward
(5′-ACGTTGGATGTGATGTTGTGATGGGCACTC-3′),
Reverse (3′-ACGTTGGATGGTCATAGTTGTTGCAAGC
CG-5′), and UEP_SEQ (AGAGCTGCTGAGAACT). The
ABCG2 1143 C/T was amplified using the primers 1143
C/T Forward (5′-ACGTTGGATGACTCTGAAAGCACT
GTTTTG-3′), Reverse (3′-ACGTTGGATGCATTTGAAT
GTCAGCTAGTC-5′), and UEP_SEQ (TGTCAGCTAG
TCATAAATAAATAC). Moreover, The ABCG2 -15622
C/T was amplified using the primers ABCG2 -15622C/T
Forward (5′-ACGTTGGATGCTGGCCAAGACCCTATC
TTA-3′), Reverse (5′- AACGTTGGATGGCCACCTATCT
TTGTTCACC-3′) and UEP_SEQ (TTAGGACTACAGACA
TGC).
Finally, genotyping of ABCG2 SNPs were conducted
using matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) and
Sequenom MassARRAY system (Sequenom, San Diego,
CA, USA).
Statistical analysis
Allele frequencies of SNPs were calculated and their geno-
type distributions were assessed by Hardy-Weinberg
Equilibrium using the chi-square test.
PFS and OS with 95% confidence intervals (CI) were eval-
uated with censored survival time methods. Kaplan-Meier
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log-rank test.
The univariate analysis included several clinical char-
acteristics. Baseline characteristics included gender, age
(≤63 vs >63), histology (adenocarcinoma vs others),
smoking (never vs ever). A multivariate logistic regres-
sion model was used to analyze the clinical outcomes in
NSCLC patients treated by TKIs and estimate the ad-
justed hazard ratio (HR) and its 95% CI. Cox propor-
tional hazards model was applied to evaluate the
association between OS and clinical or genomic charac-
teristics and estimate the adjusted HR and its 95% CI.
All tests were 2-sided and a p-value < 0.05 was consid-
ered statistically significant. All statistical analyses were
carried out using SPSS 18.0 (SPSS Inc., Chicago, IL,
USA) software.
Results
Characteristics of the study patients
The detailed characteristics of patients were given in
Table 1. There were 53 male and 47 female patients en-
rolled for study. The average age was 64 years. Sixty-six pa-
tients had history of cigarette smoking. There were 81 cases
of adenocarcinomas in pathological classification of primary
tumors. Patients with EGFR gene mutation accounted forTable 1 Main clinical characteristics for the non-small cell
lung cancer (NSCLC) patients


















Patients treated with TKI
Gefitinib 39 39%
Erlotinib 10 10%
Icotinib 21 21%21% of total cases. Totally, 39, 10 and 21 patients separately
received gefitinib, erlotinib or icotinib in our study.
ABCG2 gene polymorphisms
The genotyping of ABCG2 34 G/A, 421 C/A, 1143 C/T
and −15622 C/T were performed in all these 100 pa-
tients. Moreover, the genotyping and allele frequencies
of ABCG2 in a Chinese NSCLC population were shown
in Table 2. Regarding the ABCG2 -15622 C/T poly-
morphism, the TT genotype was observed in all patients.
Therefore, polymorphism of ABCG2 -15622 C/T was
not investigated in the following steps.
Association between polymorphisms of ABCG2 and
clinical characteristics
The association between polymorphisms of ABCG2 and
clinical characteristics were presented in Table 3. No sig-
nificant correlation was found between ABCG2 polymor-
phisms (34 G/A, 421 C/A and 1143 C/T) and clinical
characteristics, including gender, age, smoking history,
histology and EGFR mutation (p > 0.05).
Association between polymorphisms of ABCG2 and
clinical outcome of TKIs therapy
The sensitivity of 70 patients subjected to TKI treatment
was presented in Table 4. None of the three SNPs (34 G/A,
p = 0.453; 421 C/A, p = 0.615 and 1143 C/T, p = 0.804) was
significantly correlated with sensitivity.
Median PFS for carriers of the A-allele and GG genotype
at position 34 of the ABCG2 gene who were treated with
TKIs therapy was 8.0 months (95% CI: 5.9-10.1, n = 45) and
6.5 months (95% CI: 4.1-8.9, n = 25), respectively. However,
no significant difference was found (p = 0.355). Similarly,
there was no significant difference in median PFS of
NSCLC patients receiving TKIs therapy between CC geno-
type and CA/AA genotype at position 421 of ABCG2 geneTable 2 Genotyping and allele frequencies of ABCG2 in a
Chinese NSCLC population
SNP Genotype Number Frequencies Allele Frequencies
34 G/A GG 36 0.36 G 0.610
GA 50 0.50 A 0.390
AA 14 0.14
421 C/A CC 53 0.53 C 0.745
CA 43 0.43 A 0.255
AA 4 0.40
1143 C/T CC 66 0.66 C 0.805
CT 29 0.29 T 0.195
TT 5 0.50
−15622 C/T CC 0 0 C 0
CT 0 0 T 1.000
TT 100 1.00
Table 3 The association between ABCG2 polymorphisms and clinical characteristics
34 G/A P-value 421 C/A P-value 1143 C/T P-value
GG AG AA CC CA AA CC TC TT
Gender 0.684 0.501 0.682
Male 19 28 6 31 20 2 34 17 2
Female 17 22 8 22 23 2 32 12 3
Age 0.725 0.167 0.517
≤64 18 29 7 28 22 4 34 18 2
>64 18 21 7 25 21 0 32 11 3
Smoking history 0.564 0.667 0.527
Never 23 32 11 34 30 2 45 17 4
Ever 13 18 3 19 13 2 21 12 1
Histology 0.955 0.816 0.535
Adenocacino 29 41 11 42 36 3 53 23 5
Others 7 9 3 11 7 1 13 6 0
EGFR mutation 0.204 0.119 0.305
Positive 7 14 0 9 10 2 15 6 0
Negative 3 6 2 9 2 0 6 4 1
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position 1143 of ABCG2 gene was higher than those with
CT or TT genotype, but no significant difference was found
(p = 0.082).
The median OS of patients with GG genotype at pos-
ition 34 of the ABCG2 gene was 18 months (95% CI:
14.9-21.1, n = 25) while the median OS for those with
other genotypes (GA or AA) was 31 months (95% CI:
22.9-39.1, n = 45). Figure 1 showed the Kaplan-Meier
curve for OS for NSCLC patients receiving TKIs therapy
in relation to ABCG2 genotypes at 34 G/A (Figure 1A),
421 C/A (Figure 1B) and 1143 C/T (Figure 1C). There
was significant difference between patients with GG
genotype and those with GA or AA genotype at position
34 of the ABCG2 gene (p = 0.005). However, there wasTable 4 Association between ABCG2 polymorphism and clinic
in 70 NSCLC patients
Clinical outcome P-value
Sensitive (n) Resistive (n)
34 G/A
GG 15 10
GA + AA 31 14 0.453
421 C/A
CC 22 13
CA + AA 24 11 0.615
1143 C/T
CC 32 16
CT + TT 14 8 0.804
PFS: progression-free survival; OS: overall survival; 95% CI: 95% confidence intervalsno significant difference between patients with CC geno-
type regarding the position 421 of ABCG2 gene and car-
riers with other genotypes (CA or AA, p = 0.823).
Similarly, no significant difference was found in 1143 C/T
polymorphism (p = 0.872).
Univariate analysis exhibited that gender (HR 1.615;
95% CI 0.922-2.955; p = 0.092), age (HR 1.371; 95% CI
0.761-2.472; p = 0.294), smoking (HR 1.477; 95% CI 0.785-
2.779; p = 0.227) and histology (HR 2.213; 95% CI 0.681-
7.194; p = 0.187) had no significant effect on OS. Similarly,
ABCG2 C421A as well as C1143T polymorphism also had
no significant influence on the OS. On the contrary,
ABCG2 G34A was a statistically significant factor for the
OS endpoints in all patients (HR 1.526; 95% CI 1.128-2.065;
p = 0.006). Gender had no significant influence. Theal outcome of tyrosine kinase inhibitions (TKIs) therapy
PFS (95% CI) P-value OS (95% CI) P-value
6.5 (4.1-8.9) 18 (14.9-21.1)
8.0 (5.9-10.1) 0.355 31 (22.9-39.1) 0.005
7.0 (3.7-10.4) 19 (7.4-30.6)
8.0 (6.1-9.9) 0.089 28 (15.0-41.0) 0.823
8.0 (5.4-10.7) 21 (11.0-30.0)
6.5 (3.12-9.8) 0.082 27.5 (15.4-39.6) 0.872
.
Figure 1 Kaplan–Meier curve shows overall survival (OS) for the
non-small-cell lung cancer (NSCLC) patients receiving tyrosine kinase
inhibitors drugs related to ATP binding cassette superfamily G member
2 (ABCG2) genotypes at 34 G/A (A, p= 0.005), 421 C/A (B, p= 0.823) and
1143 C/T (C, p= 0.872).
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Table S1.
Similarly, the OS was independently associated with
ABCG2 G34A (HR 1.765; 95% CI 1.193-2.611; p = 0.004)
based on multivariate analysis of gender, age, smoking,histology, and the ABCG2 C421A as well as C1143T poly-
morphism (Additional file 1: Table S1).
Discussion
In the present study, we detected the polymorphism of
ABCG2 34 G/A, 421 C/A, 1143 C/T and −15622 C/T in
100 Chinese advanced NSCLC patients. The associations
between ABCG2 polymorphisms and clinical characteris-
tics and clinical outcome for patients treated with TKIs
therapy were analyzed. The results showed that three poly-
morphisms (34 G/A, 421 C/A and 1143 C/T) of the ABCG2
gene occurred more frequently compared with −15622 C/T
in Chinese advanced NSCLC patients. No significant cor-
relations were found between ABCG2 polymorphisms
(34 G/A, 421 C/A and 1143 C/T) and clinical characteris-
tics. The median OS of patients with GG genotype at pos-
ition 34 of the ABCG2 gene was significantly shorter than
those with GA/AA genotype.
The polymorphisms of ABCG2 gene are different in dif-
ferent ethnic groups [16]. The allele frequency of the
34 G/A variant in East Asian populations including
Chinese (20.0%), Koreans (19.8%) and Japanese (15.0-19.0%)
is very similar [16]. However, it is much lower than that in
Southeast Asians (45%) and higher than other ethnic
groups including Caucasian (1.7–10.3%), African-American
(6.3%) and Middle Eastern (5.0%) populations [16]. Simi-
larly, the frequency of 421 C/A variant is similar to the
Asian populations, but very different to the other ethnic
groups [16]. In Caucasians, the frequency of 421 C/A vari-
ant was reported to be 28% [18]. In this study, the frequen-
cies of ABCG2 polymorphisms 34 G/A, 421 C/A and 1143
C/T were higher than −15622 C/T, which was consistent
with a previous study reported by Kobayashi et al. [19] sug-
gestting that the most frequent ABCG2 polymorphisms
were 34 G/A and 421 C/A. Interestingly, all patients in this
study were observed TT genotype at −15622 C/T position.
As far as we know, this gene has not been investigated in
other Asian populations. Therefore, further studies could
be conducted to determine the polymorphism of −15622
C/T in Asian population and its potential impact.
The polymorphisms of ABCG2 gene are associated
with the protein expression or function in NSCLC [20].
High ABCG2 expression has been correlated with multi-
drug resistance and poorer clinical outcomes, as drug
transporter has the ability to extrude its drug substrates
out of the cells, thereby decreasing their intracellular ac-
cumulation [21,22]. Therefore, ABCG2 plays an import-
ant role in determining drug disposition. According to
the Kaplan-Meier curve and Cox regression analysis in
our study, ABCG2 34 G/A showed a significant positive
influence on the OS for carriers of the A allele in
NSCLC patients, which led to longer OS than those with
wild type (GG). Significantly, our results were in line
with the previous studies which reported that ABCG2
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of grade 2 of worse skin rash in NSCLC patients treated by
gefitinib [23] and the occurrence of skin rash was related
with improved survival with gefitinib for patients with ad-
vanced NSCLC [24]. It has been reported that 34 G/A may
decrease the ABCG2 protein expression [25], and thus re-
duce the transporter activity and increase drug accumula-
tion in the variant ABCG2-expressing cells [26]. It may
cause a better response to the drug. In addition, there was
no significant influence of ABCG2 421 C/A on any of the
clinical outcome of TKI therapy in our study, which was
consistent with a previous study that there was no evident
association between ABCG2 421 C/A polymorphisms and
susceptibility to gefitinib-induced adverse effects in Japanese
population [27]. Moreover, Rudin et al. have demonstrated
that there are no correlation between ABCG2 421C/A poly-
morphism and side-effects in erlotinib-treated patients [28].
It has been reported that ABCG2 421 C/A polymorphism
can decrease ABCG2 protein expression, and thus reduce
the transporter activity and indicate a better clinical out-
come [29-31]. Significantly, ABCG2 421 C/A polymorphism
has been related with higher accumulation of erlotinib and
gefitinib [32]. However, Cusatis et al. [14] found that there
was a strong association between the ABCG2 421 C/A poly-
morphism and diarrhea in NSCLC patients treated with ge-
fitinib. Regarding to 1143 C/T and −15622 C/T, some
researchers found a decreased protein expression related to
these two polymorphisms [31], while others found no rela-
tion between them [18]. Therefore, the relationships be-
tween ABCG2 polymorphisms and clinical outcome of the
targeted therapy are worthy to be further investigated.
Taking these results into account, ABCG2 34 G/A may be
a possible predictor of the clinical outcome of TKIs ther-
apy in Chinese NSCLC patients.
Although the correlation between ABCG2 gene polymor-
phisms and outcome and prognosis of TKIs therapy in
Chinese NSCLC patients was estimated, some limitations
still remain in this study. The number of patients treated
with TKI therapy was only 70. Moreover, the TKI-induced
side effects (such as diarrhea and skin toxicity) were not
considered in this study. Additionally, exon 19 deletion
mutation and exon 21 point mutation in EGFR were not
described for this patient set. The relation between ABCG2
SNPs and gefitinib, erlotinib as well as icotinib was not an-
alyzed separately. Therefore, further studies with large pa-
tients should be needed to confirm our results, TKIs
induced side effects, exon 19 deletion mutation and exon
21 point mutation in EGFR, and relation between ABCG2
SNPs and gefitinib, erlotinib as well as icotinib should be
taken into consideration in further study.
Conclusions
In conclusion, a strong association between the ABCG2
34 G/A polymorphism and the OS of NSCLC patientstreated with TKIs (gefitinib, erlotinib and icotinib) indi-
cates that ABCG2 34 G/A may be a possible predictor of
the clinical outcome of TKIs therapy in Chinese NSCLC
patients.
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